top of page
Helping patients understand KRAS cancer research.
KRAS Cancer News & Updates
Lung Cancer Patients Want to Know About Daraxonrasib: What Does RAS Mutant Mean?
By Terri Conneran, Founder, KRAS Kickers Reviewed for clinical accuracy by Salman R. Punekar, MD, MSc, Perlmutter Cancer Center at NYU Langone Health For this daraxonrasib lung cancer study, eligible RAS mutations were found at G12, G13, or Q61. The exact gene and exact mutation still matter because different RAS mutations can behave differently and may affect treatment or clinical trial options. For example, KRAS G12D, KRAS G12V, and KRAS G12C are all RAS mutations, but they
Rare Pancreas cancer FGFR + KRAS trial - comes to you
Rare Pancreatic cancer trial comes to you! FGFR + KRAS
Terri Conneran KRAS Kickers
May 19, 2025
KICKING KRAS LUNG CANCER!
Upstage Lung Cancer heard the power of hope to kick cancer from Terri Conneran
Terri Conneran KRAS Kickers
Dec 19, 2024
Getting ahold of KRAS Science: Visiting Kevan Shokat at his UCSF Lab
By the time I met Kevan Shokat, KRAS G12D was already the name of the devil my body was fighting.
Then Kevan did something extraordinary. He made me a three dimensional model of KRAS, had it painted, and sent it to me with a handwritten letter.
How KRAS Became Druggable: Kevan Shokat and the Pocket That Opened a New Era of RAS Drugs
more than 60 additional drugs targeting the RAS family are now in development. What began with a chemical foothold in KRAS G12C has become an expanding field of RAS drug discovery. Why This Matters for People With KRAS Cancer The science also explains why knowing the exact KRAS variant matters.
Where can patients find the NCCN guidelines used to guide cancer treatment?
NCCN Guidelines help clinicians determine what evaluations are appropriate, which treatment options are supported by current evidence, when additional testing may be important, and how care may change as a cancer changes.For patients, NCCN offers a version for patients.
bottom of page